

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(10) International Publication Number  
**WO 2017/070395 A8**


(43) International Publication Date  
27 April 2017 (27.04.2017)

- (51) International Patent Classification:  
*A61K 31/436* (2006.01)      *C12N 5/0783* (2010.01)  
*C12N 5/078* (2010.01)
- (21) International Application Number:  
PCT/US2016/057983
- (22) International Filing Date:  
20 October 2016 (20.10.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/244,036      20 October 2015 (20.10.2015)      US
- (71) Applicants: **KITE PHARMA, INC.** [US/US]; 2225 Colorado Avenue, Santa Monica, California 90404 (US). **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325 MSC 7660, Bethesda, Maryland 20892-7660 (US).
- (72) Inventors: **PEREZ, Arianne**; 2225 Colorado Avenue, Santa Monica, California 90404 (US). **SABATINO, Marianna**; 2225 Colorado Avenue, Santa Monica, California 90404 (US). **ROSENBERG, Steven A.**; c/o Center for Cancer Research, National Cancer Institute, Building 10 - Hatfield CRC, Room 3-3940, Bethesda, Maryland 20892 (US).

- RESTIFO, Nicholas P.**; Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325 MSC 7660, Bethesda, Maryland 20892 (US).
- (74) Agent: **KIM, Ji-Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF PREPARING T CELLS FOR T CELL THERAPY

**FIG. 1A**  
Naive&Tcm CD4 d7



(57) Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.

WO 2017/070395 A8

**Published:**

- *with international search report (Art. 21(3))*
- *with amended claims (Art. 19(1))*

**(48) Date of publication of this corrected version:**

03 May 2018 (03.05.2018)

**(15) Information about Correction:**

see Notice of 03 May 2018 (03.05.2018)